US 10421752
Compositions and methods for inhibition of the JAK pathway
granted A61KA61K31/343A61K31/436
Quick answer
US patent 10421752 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/343, A61K31/436, A61K31/505, A61K31/506